
Tarsus: A private, clinical-stage biopharmaceutical firm based in Irvine, California.
Tarsus Pharmaceuticals, founded in Irvine, California, is a privately held, clinical-stage biopharmaceutical company. The company's core mission is to revolutionize treatment for patients with limited therapeutic options by delivering innovative therapies. Tarsus focuses on developing novel therapeutics, starting with treatments for eye diseases. Their flagship product addresses Demodex blepharitis, providing an FDA-approved solution for millions of patients suffering from this condition.
Notable figures affiliated with Tarsus include a team of experienced biopharmaceutical professionals dedicated to advancing medical treatments. The company has achieved significant milestones, including the development and FDA approval of their treatment for Demodex blepharitis. Tarsus's impact lies in its commitment to addressing unmet medical needs, thereby improving patient outcomes and setting new standards in therapeutic ingenuity.
Telsar Pharma

Tigris Pharmaceuticals
tigrispharma.com

Surface Pharmaceuticals
surfacepharma.com

Arcutis Biotherapeutics
arcutis.com

Thar Pharmaceuticals
tharpharma.com

Thesan Pharmaceuticals
thesanpharma.com

Theracos
theracos.com

ARS Pharmaceuticals
ars-pharma.com

Visiox
visioxpharma.com

Tisbury Pharmaceuticals

Terns Pharmaceuticals
ternspharma.com

Corbus Pharmaceuticals Holdings
corbuspharma.com

TearClear
tearclear.com

TBT Pharma
tbtpharma.com

Iacta Pharmaceuticals
Companies similar to Tarsus Pharmaceuticals include Telsar Pharma, Tigris Pharmaceuticals, Surface Pharmaceuticals and Arcutis Biotherapeutics.
Tarsus Pharmaceuticals was founded in 2017.
Tarsus Pharmaceuticals' headquarters is located in Irvine, CA, US.
Tarsus Pharmaceuticals' most recent funding round was for $100M (USD) in August 2023.
As of Aug 1, 2023, Tarsus Pharmaceuticals has raised a total of $410.6M (USD).
Tarsus Pharmaceuticals has 251 employees as of Feb 6, 2024.